英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字,中文词皆可:

heterogeneously    
ad. 不同类地

不同类地

Heterogeneous \Het`er*o*ge"ne*ous\, a. [Gr. ?; ? ? race, kind;
akin to E. kin: cf. F. h['e]t['e]rog[`e]ne.]
Differing in kind; having unlike qualities; possessed of
different characteristics; dissimilar; -- opposed to
homogeneous, and said of two or more connected objects, or of
a conglomerate mass, considered in respect to the parts of
which it is made up. -- {Het`er*o*ge"ne*ous*ly}, adv. --
{Het`er*o*ge"ne*ous*ness}, n.
[1913 Webster]

{Heterogeneous nouns} (Gram.), nouns having different genders
in the singular and plural numbers; as, hic locus, of the
masculine gender in the singular, and hi loci and h[ae]c
loca, both masculine and neuter in the plural; hoc
c[ae]lum, neuter in the singular; hi c[ae]li, masculine in
the plural.

{Heterogeneous quantities} (Math.), such quantities as are
incapable of being compared together in respect to
magnitude, and surfaces and solids.

{Heterogeneous surds} (Math.), surds having different radical
signs.
[1913 Webster]


请选择你想看的字典辞典:
单词字典翻译
heterogeneously查看 heterogeneously 在百度字典中的解释百度英翻中〔查看〕
heterogeneously查看 heterogeneously 在Google字典中的解释Google英翻中〔查看〕
heterogeneously查看 heterogeneously 在Yahoo字典中的解释Yahoo英翻中〔查看〕





安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Advanced and metastatic prostate cancer: ESMO Clinical . . .
    This includes metastatic castration-sensitive prostate cancer (mCSPC), non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-resistant prostate cancer (mCRPC) The management of early-stage disease is covered in the ESMO CPG for local and locoregional prostate cancer 1
  • Niraparib and abiraterone acetate plus prednisone for HRR . . .
    We hypothesized that PARP inhibition within 6 months of starting androgen deprivation therapy for metastatic castration-sensitive prostate cancer (mCSPC) could be effective and improve
  • Prostate Cancer, Version 3. 2026, NCCN Clinical Practice . . .
    The NCCN Guidelines for Prostate Cancer provide a framework on which to base decisions for patients with prostate cancer across the disease spectrum The Guidelines sections included in this article focus on metastatic castration-sensitive prostate cancer (mCSPC), nonmetastatic castration-resistant prostate cancer (CRPC), and metastatic CRPC (mCRPC) For patients with mCSPC, disease
  • Efficacy and safety of treatments for metastatic castration . . .
    Metastatic prostate cancer that has not previously been treated with ADT is considered to be castration-sensitive prostate cancer (mCSPC)
  • Metastatic Castration-Sensitive Prostate Cancer: Optimizing . . .
    Further incremental progress in the outcome of patients with mCSPC came from the addition of novel agents, docetaxel or abiraterone, to ADT for more aggressive up-front treatment of metastatic prostate cancer
  • Advanced and metastatic prostate cancer: ESMO Clinical . . .
    This includes metastatic castration-sensitive prostate cancer (mCSPC), non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-resistant prostate cancer (mCRPC) The management of early-stage disease is covered in the ESMO CPG for local and locoregional prostate cancer 1
  • Packing the Punch: Current and Emerging Treatment Strategies . . .
    Purpose of Review Prostate cancer remains a significant source of morbidity and mortality worldwide, with metastatic castration-sensitive disease (mCSPC) representing a complex therapeutic challenge This review explores how a deeper understanding of the androgen receptor axis has shifted mCSPC management from monotherapy to more intense treatment We discuss emerging data on triplet regimens
  • Chemotherapy-Forward Management of Advanced Prostate Cancer . . .
    Taxane chemotherapy remains a durable backbone in advanced prostate cancer, but its clinical value is increasingly determined by timing, sequencing, and deliverability We synthesize pivotal randomized trials and contemporary guidance to provide a chemotherapy-forward framework spanning metastatic castration-sensitive prostate cancer (mCSPC) and metastatic castration-resistant prostate cancer
  • Metastatic castration-resistant prostate cancer (mCRPC)
    Metastatic prostate cancer happens when the cancer spreads from the prostate to other parts of the body Sometimes the cancer spreads and hormone therapy helps control it This is called metastatic castration-sensitive prostate cancer (mCSPC) If the cancer spreads and no longer responds to hormone therapy medicines, it's considered mCRPC
  • ASPIRE: A randomized phase III trial of androgen deprivation . . .
    ASPIRE: A randomized phase III trial of androgen deprivation therapy (ADT) plus apalutamide (A) with or without docetaxel (D) in metastatic castration-sensitive prostate cancer (mCSPC) stratified by tumor suppressor gene alterations (Alliance A032302)





中文字典-英文字典  2005-2009